Cassava Sciences Stock Price, News & Analysis (NASDAQ:SAVA)

$1.22
+0.03 (+2.52 %)
(As of 09/23/2019 01:19 PM ET)
Today's Range
$1.22
Now: $1.22
$1.25
50-Day Range
$1.0499
MA: $1.25
$1.41
52-Week Range
$0.76
Now: $1.22
$2.99
Volume480 shs
Average Volume458,586 shs
Market Capitalization$21.01 million
P/E RatioN/A
Dividend YieldN/A
Beta1.68
Cassava Sciences, Inc., a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SAVA
CUSIPN/A
CIKN/A
Phone512-501-2444

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.14 per share

Profitability

Net Income$-6,560,000.00

Miscellaneous

Employees9
Market Cap$21.01 million
Next Earnings Date11/4/2019 (Estimated)
OptionableNot Optionable

Receive SAVA News and Ratings via Email

Sign-up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter.


Cassava Sciences (NASDAQ:SAVA) Frequently Asked Questions

What is Cassava Sciences' stock symbol?

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

How were Cassava Sciences' earnings last quarter?

Cassava Sciences Inc (NASDAQ:SAVA) issued its quarterly earnings results on Monday, August, 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.05. View Cassava Sciences' Earnings History.

When is Cassava Sciences' next earnings date?

Cassava Sciences is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Cassava Sciences.

What price target have analysts set for SAVA?

2 analysts have issued twelve-month target prices for Cassava Sciences' stock. Their predictions range from $3.00 to $3.00. On average, they anticipate Cassava Sciences' share price to reach $3.00 in the next twelve months. This suggests a possible upside of 145.9% from the stock's current price. View Analyst Price Targets for Cassava Sciences.

What is the consensus analysts' recommendation for Cassava Sciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cassava Sciences.

What are Wall Street analysts saying about Cassava Sciences stock?

Here are some recent quotes from research analysts about Cassava Sciences stock:
  • 1. Maxim Group analysts commented, "Cassava announced the initiation of Phase 2b for its lead therapeutic candidate PTI-125 in mild-moderate Alzheimer’s disease (AD). The first two patients of the trial have been dosed. The Phase 2b initiation follows positive Phase 2a results (see note 9/9, LINK) in which a 100% responder rate and statistically significant reductions (p<0.001) in key AD biomarkers were noted, including an improved cerebrospinal fluid (CSF) P-tau to Aβ42 ratio (p<0.001), which has been found to correlate with cognitive deficiencies."" (9/18/2019)
  • 2. HC Wainwright analysts commented, "Our $3 PT was derived by using a weighted- average cost of capital of 13% for Cassava shares to discount free cash flows from our projection of annual sales of PTI-125 in Alzheimer’s disease, and dividing them by our projected number of shares for each year to account for the effects of share dilution." (8/16/2019)

Has Cassava Sciences been receiving favorable news coverage?

Media stories about SAVA stock have trended somewhat negative on Monday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cassava Sciences earned a news impact score of -1.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Cassava Sciences.

Who are some of Cassava Sciences' key competitors?

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Athenex (ATNX), Achillion Pharmaceuticals (ACHN), Amarin (AMRN), Catalyst Biosciences (CBIO), Celsion (CLSN), Gilead Sciences (GILD), Aphria (APHA), Acorda Therapeutics (ACOR), Acasti Pharma (ACST) and Advanced Micro Devices (AMD).

Who are Cassava Sciences' key executives?

Cassava Sciences' management team includes the folowing people:
  • Mr. Remi Barbier, Founder, Chairman, CEO & Pres (Age 59)
  • Mr. Eric J. Schoen, Chief Financial Officer (Age 51)
  • Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 76)
  • Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3.97%), BlackRock Inc. (1.09%), Vanguard Group Inc. (0.97%), Envestnet Asset Management Inc. (0.37%) and Susquehanna International Group LLP (0.13%). View Institutional Ownership Trends for Cassava Sciences.

Which institutional investors are selling Cassava Sciences stock?

SAVA stock was sold by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP, BlackRock Inc. and Vanguard Group Inc.. View Insider Buying and Selling for Cassava Sciences.

Which institutional investors are buying Cassava Sciences stock?

SAVA stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Envestnet Asset Management Inc.. View Insider Buying and Selling for Cassava Sciences.

How do I buy shares of Cassava Sciences?

Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cassava Sciences' stock price today?

One share of SAVA stock can currently be purchased for approximately $1.22.

How big of a company is Cassava Sciences?

Cassava Sciences has a market capitalization of $21.01 million. The company earns $-6,560,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Cassava Sciences employs 9 workers across the globe.View Additional Information About Cassava Sciences.

What is Cassava Sciences' official website?

The official website for Cassava Sciences is http://www.cassavasciences.com/.

How can I contact Cassava Sciences?

Cassava Sciences' mailing address is 7801 NORTH CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company can be reached via phone at 512-501-2444 or via email at [email protected]


MarketBeat Community Rating for Cassava Sciences (NASDAQ SAVA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  25 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  47
MarketBeat's community ratings are surveys of what our community members think about Cassava Sciences and other stocks. Vote "Outperform" if you believe SAVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel